Moderna shares fell 17% in one session after leaked data from a phase 3 trial of intismeran autogene combined with Merck's Keytruda, though the leaked results showed the drug combo cut the risk of recurrence or death by 42% in certain melanoma patients versus Keytruda alone, and by 58% after six months. The stock has still climbed more than 500% this year, trading near $200 versus an average Wall Street 12-month price estimate of $135. The author sees the dip as possibly a buying opportunity for long-term investors who want to open or add to a position, while cautioning that the stock remains sensitive to trial data and may see further pullbacks. Moderna currently has four commercialized products in the U.S., all respiratory vaccines.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?
Read the original on Yahoo Finance ↗
Keywords
ModernapharmaceuticalsMerckhealthcare
Open a keyword to see other news on the same topic.
Related news
- Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Moderna shares fell 4% to $193.62 in morning trading, extending an 18% plunge from the prior session, even though full late-stage data for its personalized melanoma vaccine, given with Merck's Keytruda, came back positive. Compared with Keytruda alone, the combination cut the risk of melanoma recurrence or death, a result near analyst expectations but short of the highest hopes built during a rally that began in August. The vaccine carries far more weight for Moderna, whose approved products are all respiratory vaccines, while for Merck it is an add-on to Keytruda; Merck fell 0.8% to $146 and Pfizer 0.7% to $30.22. The iShares Biotechnology ETF was unchanged at $209.54, suggesting the slide is company-specific. The full data will be presented at a medical conference this weekend.
- Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Biotech news this week focuses on kidney cancer, multiple sclerosis, Huntington's disease and personalized cancer treatment, as Arcus Biosciences (RCUS), Alnylam (ALNY), Moderna (MRNA) and Merck (MRK) release clinical updates alongside earnings and conferences. Last week, the health care ETF XLV gained 3%, outperforming SPY (down 2%) and QQQ (down 6%), while the biotech ETF XBI fell 6%. Arcus will present kidney-cancer data from its ARC-20 study of Casdatifan, Achieve Life Sciences will report year-long Cytisinicline findings for smoking cessation after a June FDA rejection it says concerned manufacturing and labeling, and Alnylam will share initial Phase 1 ALN-HTT02 results for Huntington's disease. Moderna and Merck will present Phase 3 INTerpath-001 melanoma data on Saturday, comparing individualized treatment intismeran autogene plus Keytruda with Keytruda alone after surgery, while a number of other companies will present multiple sclerosis updates through the week.
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
Merck CEO Rob Davis told CNBC that the personalized cancer vaccine developed with Moderna currently takes about six weeks from tumor sequencing to hospital delivery, and he expects that timeline to shorten over time, though supply and market readiness come first. The vaccine targets each patient's unique tumor mutations and is paired with Keytruda; in August, the companies released positive early data from a late-stage melanoma trial. Merck also opened a 120,000-square-foot R&D facility in West Point, Pennsylvania, as Keytruda nears loss of exclusivity, with its core U.S. compound patent expiring in December 2028. The company plans $65 billion in external acquisitions and licensing deals over five years to bolster its pipeline. A Dutch court has blocked Merck from selling subcutaneous Keytruda in eight European countries, and Merck says it will appeal.
- Moderna shares plunge after leak of partial cancer vaccine data despite positive results
Moderna shares fell as much as 25% on Thursday after partial data from its cancer vaccine developed with Merck leaked ahead of the full results, which were released later that day. The full data appeared positive relative to Wall Street expectations: the personalized vaccine intismeran autogene, combined with Keytruda, reduced the risk of recurrence or death in certain melanoma patients by 42% versus Keytruda alone, and cut the risk of distant spread or death by 38%. Detailed phase 3 results will be presented at the European Society for Medical Oncology conference this weekend. Investors view the vaccine as a possible breakthrough that could extend to other cancers, and the stock has spiked more than 530% this year on high expectations.
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
Related markets
Latest news
- What we want to see when this data center stock reports earnings next week
Stocks mostly fell on Friday, with the Dow down about 1% as selling spread beyond the AI trade, and West Texas Intermediate crude rose above $103 per barrel on renewed US-Iran tensions. Palo Alto Networks and CrowdStrike were the Investing Club's best performers, each up more than 6%, while the Club exited Broadcom. Meta shares fell again, extending Thursday's nearly 7% decline, as investors questioned how its AI buildout will be funded after free cash flow turned negative for the first time since its 2012 IPO. The Club is sticking with Meta given its strong fundamentals and Muse roadmap, and it added a few shares of GE Vernova during Thursday's sell-off. Ahead of GE Vernova's earnings next week, the Club wants to see continued strong orders for heavy-duty gas turbines and strong pricing.
- SpaceX earnings, tech selloff lead to rocky week for investors
SpaceX shares rose after a third-quarter report beat estimates and Elon Musk openly backed a possible merger with Tesla, but a Thursday tech sell-off erased those gains. Connectivity revenue, mostly from Starlink, climbed 69% to $5.2 billion, and Starlink added 1.6 million subscribers, bringing broadband consumer subscribers to just under 14 million. Bloomberg reported SpaceX is in talks with Crown Castle and American Tower to lease space on 80,000 US cell sites to build out a terrestrial network. SpaceX and Tesla have each formed special committees to explore a combination worth about $3.5 trillion, though Musk flagged the hurdle of approval from 50% of Tesla shareholders and Reuters reported his endorsement could delay the process by weeks. The Thursday slide also came as about 911.5 million insider shares became eligible for sale.
- Wells Fargo Names Top Pick Ahead of Q3 Earnings
Wells Fargo named Amazon its top long position and preferred mega-cap stock heading into third-quarter earnings, expecting another positive revision to AWS revenue and operating income. The firm cites AWS revenue acceleration and strong margins as the main drivers, while acknowledging near-term operating income risks from fuel costs and longer-term uncertainty around agentic commerce. It views Amazon's setup as more straightforward than other mega-cap tech names, where hedge fund positioning adds complications. Wells Fargo also sees AWS as the key driver of positive estimate revisions after the report.
- SEC flags tokenization as high-risk area in 2027 market examinations
The SEC added tokenization to its fiscal 2027 examination priorities, flagging tokenized securities as an emerging market risk alongside quantum computing and extended trading hours. Tokenization is an area of focus for critical market infrastructure and a high-risk area at clearing agencies, alongside default management, securities lending and operational risks. Cryptocurrencies, however, remain absent as a standalone examination priority for a second consecutive year, after the fiscal 2025 priorities included a dedicated section on crypto assets. The move comes as traditional firms expand into tokenized securities, including an OKX and Intercontinental Exchange joint venture that filed to offer tokenized shares in more than 60 US-listed companies.
- How Broker Downgrade Has Changed The Case For Agnico Eagle Stock
Freedom Broker downgraded Agnico Eagle Mines, citing operational risks at Canadian Malartic and Odyssey and trimmed earnings and EBITDA projections after revenue came in slightly below estimates. The broker noted the stock trades at a premium to peers, so any execution issues or cost inflation could weigh more heavily on profit expectations. The company, with long-life gold assets in Canada, Australia, Finland and Mexico, reports a return on equity of 20.5% and a net profit margin of 40.4%. Forecasts now point to declining earnings and revenue over the next three years, and the shares have fallen about 6% over one day and roughly 13% over the past month ahead of the October 28 earnings release. Some pessimistic analysts see revenue falling toward US$10.2b and earnings toward roughly US$4.8b by 2029, though those forecasts predate the downgrade.
- As the U.S. Pulls Chip Making Back Home, the Toolmakers Win First
Chipmaking is being pulled back to the U.S., pouring billions into new factories and creating strong demand for equipment. In July, TSMC added $100 billion to its Arizona plans, lifting its planned U.S. investment to $265 billion, while Micron raised its U.S. spending plan to more than $250 billion through 2035. Tool orders can arrive before a new fab reaches full production. The article argues that toolmakers such as ASML and Applied Materials get paid first, while fab operators like Intel, TSMC and Micron face their own risks. ASML trades at a P/E above 40, and export restrictions or Taiwan tensions could disrupt its sales.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.